Abstract
Purpose of reviewAlthough nontuberculous mycobacterial pulmonary disease is increasing in incidence, outcomes remain less than optimal highlighting the unmet need for developing novel therapies.Recent findingsSeveral new antibiotic formulations, novel antibiotics, and novel nonantibiotic treatments have recently demonstrated positive results in treating nontuberculous mycobacterial pulmonary disease.SummaryPromising novel therapies are currently under investigation fueling much needed interest and enthusiasm in the nontuberculous mycobacterial pulmonary disease space and will hopefully lead to improved understanding and outcomes in this complex disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 176-184 |
| Number of pages | 9 |
| Journal | Current Opinion in Infectious Diseases |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 1 2022 |
Keywords
- antibacterial agents
- bacteriophages
- lung disease
- nontuberculous mycobacteria
- therapy
ASJC Scopus subject areas
- Medicine(all)